Micro-cap Losers: Eleven Biotherapeutics Inc (NASDAQ:EBIO), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), Derma Sciences Inc (NASDAQ:DSCI), Blyth, Inc. (NYSE:BTH)

Eleven Biotherapeutics Inc (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, on Apr 01, 2014  announced that it has been added as a member of the Russell 2000® and Russell 3000® Indexes after the close of market yesterday, March 31, 2014.Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index, which measures the performance of the largest 3,000 U.S. companies. Members of the Russell 2000® Index are also included in the Russell Global Index.Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares after opening at $15.72 moved to $15.72 on last trade day and at the end of the day closed at $14.68. Company price to sales ratio in past twelve months was calculated as 296.17 and price to cash ratio as 60.75. Eleven Biotherapeutics Inc (NASDAQ:EBIO) showed a negative weekly performance of -7.67%.

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig plan presentations highlighting Navidea’s PET imaging agent, NAV4694, at the German Society of Nuclear Medicine Annual Congress in Hannover, Germany, March 26-29, 2014. NAV4694 is an investigational Fluorine-18 labeled beta-amyloid imaging agent currently being evaluated in late stage clinical trials for use as an aid in differential diagnosis and to monitor progression of Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI) and other forms of neurodegenerative dementia. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) shares fell -6.32% in last trading session and ended the day on $1.78. NAVB its return on assets is -126.60%. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) yearly performance is -32.83%.

Derma Sciences Inc (NASDAQ:DSCI)  A tissue regeneration and burn care company focused on advanced wound care, reported financial and operating results for the three months and year ended December 31, 2013. Highlights of the fourth quarter of 2013 and recent weeks include:Expanded the Advanced Wound Care (AWC) product line and entered the $500 million skin substitute market by licensing the AMNIO family of placental-derived tissue productsDerma Sciences Inc (NASDAQ:DSCI) shares moved down -6.34% in last trading session and was closed at $11.08, while trading in range of $11.01-$11.98. Derma Sciences Inc (NASDAQ:DSCI)  year to date performance is 2.40%.

Blyth, Inc. (NYSE: BTH), a direct to consumer company and leading designer and marketer of candles and accessories for the home, as well as health & wellness products sold through the direct selling and direct marketing channels, announced that the United States District Court for the District of Connecticut granted the defendants’ motion to dismiss the federal securities class action lawsuit that had been pending against Blyth and others. Blyth, Inc. (NYSE:BTH) weekly performance is -5.19%. On last trading day company shares ended up $10.05. Blyth, Inc. (NYSE:BTH) distance from 50-day simple moving average is 3.91%. Analysts mean target price for the company is $40.00.